同源康医药-B(02410.HK)：撤销监事会

Core Viewpoint - The company proposes amendments to its articles of association to innovate its organizational structure and enhance the protection of minority shareholders' rights, while also abolishing the supervisory board and assigning its functions to the audit committee of the board of directors, effective from July 1, 2024, in accordance with the revised Company Law of the People's Republic of China [1] Group 1 - The company aims to reform its organizational structure [1] - The amendments are intended to strengthen the protection of minority shareholders' rights [1] - The supervisory board will be abolished, with its powers transferred to the audit committee [1]